Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

January 2025 Newsletter

Thursday, January 30, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has made significant strides in its clinical research, including the initiation of a Phase 1/2a study for BetaBart (RV-01) and receiving IND approval from the US FDA. The company has also reported positive updates across four of its programs, indicating progress in its therapeutic developments. Additionally, Dr. Oliver Sartor has been appointed to the Scientific Advisory Board.
Price reaction · baseline $4.76 (2025-01-30T20:22:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • Positive clinical updates have been reported across four programs.
  • The company received IND approval from the US FDA for a new therapeutic study.

Full Press Release Details

• Updates
• PDF
• January 30, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• December 10, 2024
• Announcements
• November 29, 2022
• Announcements
• November 29, 2022
• Investor Presentations
• November 16, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the latest update from Radiopharm Theranostics?

Radiopharm Theranostics has initiated a Phase 1/2a clinical study for BetaBart (RV-01).

Who was appointed to the Scientific Advisory Board?

Dr. Oliver Sartor has been appointed to the Radiopharm Scientific Advisory Board.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval from the US FDA to initiate a new therapeutic clinical study.

What positive updates were reported by Radiopharm?

Radiopharm provided positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical updates
Last updated: Jan 30, 2025